AMG 329
Alternative Names: AMG-329; HZN-1116; VIB-1116Latest Information Update: 19 May 2025
At a glance
- Originator Viela Bio
- Developer Amgen; Horizon Therapeutics plc
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Dendritic cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Sjogren's syndrome
- No development reported Rheumatic disorders
Most Recent Events
- 14 Nov 2024 Updated pharmacodynamics, pharmacokinetics and adverse event data from a phase I trial in Rheumatoid disorders presented at the American College of Rheumatology 2024 (ACR Convergence 2024)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Rheumatic-disorders in Poland (IV, Injection)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Rheumatic-disorders in Poland (SC, Injection)